Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes. Issue 14 (6th December 2021)

• Record Type: Journal Article
• Authors: Yanada, Masamitsu; Mizuno, Shohei; Yamasaki, Satoshi; Harada, Kaito; Konuma, Takaaki; Tamaki, Hiroya; Shingai, Naoki; Uchida, Naoyuki; Ozawa, Yukiyasu; Tanaka, Masatsugu; Onizuka, Makoto; Sawa, Masashi; Nakamae, Hirohisa; Shiratori, Souichi; Matsuoka, Ken-ichi; Eto, Tetsuya; Kawakita, Toshiro; Maruyama, Yumiko; Ichinohe, Tatsuo; Kanda, Yoshinobu; Atsuta, Yoshiko; Aoki, Jun; Yano, Shingo
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 14(2021)
• Page Start: 3411
• Page End: 3419
• Publication Date: 2021-12-06
• Subjects: Acute myeloid leukemia -- myelodysplastic syndrome -- allogeneic hematopoietic cell transplantation; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1961242
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: To evaluate whether outcomes following allogeneic hematopoietic cell transplantation differ according to disease type, a three-way comparison for patients with de novo acute myeloid leukemia (AML) ( n = 3318), AML evolving from myelodysplastic syndromes (MDS) ( n = 208), and MDS with excess blasts (MDS-EB) ( n = 994) was performed. The 5-year probabilities of overall survival (OS) for de novo AML, AML evolving from MDS, and MDS-EB were 60%, 42%, and 41% ( p < 0.001), respectively. Multivariate analysis revealed that, compared to de novo AML, AML evolving from MDS was associated with a higher risk of NRM ( p = 0.030) and MDS-EB with a higher risk of relapse ( p < 0.001), both leading to lower OS ( p = 0.010 and p < 0.001, respectively). These findings demonstrate inter-disease differences in post-transplant outcomes and highlight the needs to reduce NRM for AML evolving from MDS and to reduce relapse for MDS-EB.